60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.454 – $0.542
Volume21,550
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.72M
Price / earnings
—
Price / book
0.66×
Price / sales
1.42×
EV / sales
0.7×
EV / EBITDA
-0.1×
Profitability
Earnings per share
-$2.45
Return on assets
-201.19%
Return on equity
-329.59%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.06×
Current ratio
2.32×
Quick ratio
1.78×
Cash ratio
0.64×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SXTP, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$207.9K
$162.09K
$316.38K
$528.56K
$307.87K
$256.28K
$272.23K
$148.11K
Cost of revenue
$151.1K
$85.72K
$120.68K
$537.69K
$50.05K
$73.27K
$118.08K
$111.69K
Gross profit
$56.8K
$76.38K
$195.7K
-$9.13K
$257.82K
$183.01K
$154.15K
$36.42K
Selling, general and administrative
$1.73M
$1.89M
$1.47M
$1.51M
$1.63M
$1.72M
$1.61M
$1.22M
Research and development
$598.65K
$281.46K
$638.87K
$809.78K
$231.91K
$370.81K
$613.96K
$940.06K
Total operating expenses
$2.33M
$2.17M
$2.11M
$2.32M
$1.86M
$2.09M
$2.22M
$2.16M
Operating income
-$2.27M
-$2.09M
-$1.92M
-$2.33M
-$1.61M
-$1.91M
-$2.07M
-$2.12M
Interest expense
-$1.4K
-$1.39K
-$3.09K
-$1.71K
-$1.22K
-$1.79K
-$1.42K
-$1.47K
Income before taxes
-$2.27M
-$2.09M
-$1.44M
-$2.32M
-$1.73M
-$1.88M
-$2.05M
-$2.16M
Income taxes
$0
$0
-$1.81K
$250
$0
$0
-$751
$250
Net income
-$2.27M
-$2.09M
-$1.44M
-$2.32M
-$1.73M
-$1.88M
-$2.05M
-$2.16M
Net income attributable to common shareholders
-$2.4M
-$2.21M
-$1.57M
-$2.44M
-$1.84M
-$2M
-$2.18M
-$2.27M
EBITDA
-$2.31M
-$2.02M
-$1.72M
-$2.3M
-$1.65M
-$1.85M
$1.54M
-$2.1M
Basic earnings per share
-$0.90
-$1.28
-$1.46
-$2.64
-$5.01
-$6.25
-$9.10
-$18.60
Diluted earnings per share
-$0.90
-$1.28
-$1.46
-$2.64
-$5.01
-$6.25
-$9.10
-$18.60
Recent news
Company coverage with links to the original publishers.
Harrow (HROW) reported Q3 2026 earnings of $0.12 per share, missing the consensus estimate of $0.13 and falling short of prior year's $0.33. The pharmaceutical company posted revenues of $99.3 million, slightly beating expectations. However, the stock has declined 45.1% year-to-date and received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions, suggesting continued underperformance ahead.
60 Degrees Pharmaceuticals announced a private placement of 574,713 shares at $1.74 per share, expected to raise approximately $1.0 million in gross proceeds before fees. The offering includes series A and B warrants with exercise prices of $1.49 per share. The company plans to use net proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals reported Q3 2025 financial results with 223% net product revenue increase, but experienced a gross loss due to inventory write-off. The company is exploring new treatment indications for tafenoquine, including potential treatments for canine babesiosis and chronic babesiosis.
60 Degrees Pharmaceuticals has introduced a new 8-count bottle format for its malaria prevention drug ARAKODA, expanding options for healthcare professionals and travelers.
Sixty Degrees Pharmaceuticals announced that it will import a limited quantity of KODATEF® (tafenoquine) from Australia to ensure the continuity of ARAKODA® (tafenoquine) supply in the U.S. ARAKODA and KODATEF are identical products, and the company is taking this proactive step to maintain the availability of tafenoquine for malaria prophylaxis.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.